Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

It puts CARVYKTI in the enviable position of providing patients with longer lives, what some call the holy grail of oncology ...

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, ...

Just as the presidential election results are unfolding, investors are certain about one particular thing — a probable increase in volatility in the equity space in the course of the week. At the time ...

That said, only 14% of drugs in clinical trials make it to FDA approval ... driven by strong performance from its blockbuster blood thinner Eliquis and a lineup of key drugs aimed at long-term ...

Most of the switching is from patients on PD-1 monotherapy, where clinical data shows a more than doubling in progression-free survival ... and started a phase 3 trial in colorectal cancer last ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Despite these revisions, BMY has provided long-term guidance for its key product, Eliquis, which it co-markets ... BMY is involved in significant clinical trials, such as the RELATIVITY-104 ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Try out other networks if you're looking for a cheaper carrier or want to downsize your plan. AT&T's Cricket Wireless and ...